

**MENU**

**\*\*\*NEW & REOPENED TRIALS HIGHLIGHTED IN GREEN!\*\*\***

**JUST IN TIME TRIALS (JIT)**

**TPX-0005-01 (TRIDENT-1)**  
*MULTI-DISEASE SITES*

AML

ANAL

APL

BILIARY

BLADDER-UROTHELIAL

BRAIN

BREAST

CANCER CONTROL

CARCINOID

CLL

CML

COLON-RECTAL

ESOPHAGEAL - GASTRIC

HEAD & NECK

LYMPHOMA

MDS

MELANOMA

MERKEL

MOLECULAR STUDIES

MULTIPLE MYELOMA

NSCLC

PANCREATIC

PROSTATE

RADIATION TRIALS

RENAL CELL

SMALL CELL LUNG CANCER

VULVA



**JUST IN TIME (JIT) TRIALS**

\*Contact Disease Specific Navigator

**Brain**

[A021804](#)

**NEW!** A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

[A071702](#)

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent Glioblastoma

**Breast**

[IPI-549-03](#)

A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination With Front-line Treatment Regimens in Patients With Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma (*enrolling for breast cancer only*)

[S1706](#)

**(RT not credentialed yet)**-A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

**Endometrial**

[GY014](#)

*(Temp suspended)* A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

**Genitourinary - Rare**

[A031702](#)

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors (*temp closed - small cell carcinoma of bladder and adenocarcinoma of bladder*)

**Gastrointestinal**

[EA2197](#)

**NEW!** Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

[S1922](#)

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

[EA2187](#)

Phase II study of Pevonedistat in Combincatoin with Carbo and paclitaxel in advanced intrahepatic cholonigocarcinoma.

**Lymphoma**

<a href="#"><u>E4412</u></a>	A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
<a href="#"><u>S1608</u></a>	Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
<b>Melanoma</b>	
<a href="#"><u>EA6192</u></a>	A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)
<a href="#"><u>NEKTAR 20-214-29</u></a>	A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempedaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
<a href="#"><u>S1801</u></a>	A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
<b>Multi-Disease</b>	
<a href="#"><u>S1614</u></a>	<i>(temp closed)</i> A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or past hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
<a href="#"><u>INCB 54828-MA-TA-208</u></a> <a href="#"><u>(TEMPUS)</u></a>	A phase 2, Open Label Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)"
<b>Multiple Myeloma</b>	
<a href="#"><u>207503 - DREAMM 7</u></a> <a href="#"><u>(Optimal)</u></a>	A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Partiipants with RElapsed/Refractory Multiple Myeloma.
<b><u>Nasopharngal</u></b>	
<a href="#"><u>NRG-HN007</u></a>	An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
<b>Ovarian</b>	
<a href="#"><u>GY014</u></a>	<i>(Temp. suspended)</i> Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
<b>Pancreas</b>	

<b><u>S2001</u></b>	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
<b>Prostate</b>	
<b><u>67652000PCR3002 / AMPLITUDE</u></b>	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
<b><u>GU008</u></b>	Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy
<b>Sarcoma</b>	
<b><u>A091902</u></b>	A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
<b>Skin</b>	
<b><u>A091802</u></b>	Phase II randomized Trial of Avelumab plus cetuximab versus avelumab alone in advanced cutaneous Squamous cell carcinoma of skin
<b>Thymoma</b>	
<b><u>S1701</u></b>	A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

FEBRUARY 2021

MENU

## *Multi-Disease Sites*

Navigator - Heather x3661

[TPX-0005-01 \(TRIDENT-1\)](#)

SCHEMA

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with **Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)**



# MASTER TRIAL LIST

FEBRUARY 2021



## AML

Navigator - Heather x3661

[Connect MDS/AML](#)

*(temporarily closed)* The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry This also included ICUS.



# MASTER TRIAL LIST

FEBRUARY 2021



## ANAL

Navigator - Carrie x3621

<p><a href="#"><u>EA2176</u></a></p> <p><a href="#">SCHEMA</a></p>	<p>A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients</p>
<p><a href="#"><u>EA2182</u></a></p>	<p><b>UPH only (OSF pending)</b> A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)</p>
<p><a href="#"><u>EA2165</u></a></p>	<p><b>(RT at ILCC, OSFMC, UPH, and Galesburg)</b> A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer</p>



# MASTER TRIAL LIST

FEBRUARY 2021



*APL*

Navigator - Heather x3661

<a href="#"><u>EA9131</u></a>	A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

FEBRUARY 2021

[MENU](#)

***BILIARY***

Navigator - Carrie x3621

***No trials at this time***



# MASTER TRIAL LIST

FEBRUARY 2021



## BLADDER / UROTHELIAL

Navigator - Carrie x3621

<p><a href="#"><u>A031501</u></a></p>	<p>Phase III randomized “Adjuvant study of MK-3475 (pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma” (AMBASSADOR ) versus observation</p>
<p><a href="#"><u>A031901</u></a> <small>SCHEMA</small></p>	<p><b>NEW!</b> Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial</p>
<p><a href="#"><u>S1806</u></a></p>	<p><b>(OSF, UPH and Galesburg)</b> Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer</p>
<p><a href="#"><u>BMS CA017-078</u></a> <small>SCHEMA</small></p>	<p><b>(Peoria, Bloomington, Galesburg, and Peru)</b> -A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer</p>
<p><a href="#"><u>EA8185</u></a> <small>SCHEMA</small></p>	<p>Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)</p>



# MASTER TRIAL LIST

FEBRUARY 2021



## BRAIN

Navigator - Carrie x3621

<p><b><u>BN007</u></b></p> <p><a href="#">SCHEMA</a></p>	<p><b>(UPH, OSF, Galesburg)</b> A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma</p>
<p><b><u>N0577</u></b></p>	<p><b>(RT at OSF, RT 91, and UPH)</b> Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma</p>



**BREAST**

Navigator - Angie x3613

**NEOADJUVANT / ADJUVANT**

<p><u><a href="#">A011801</a></u></p>	<p><b>NEW!</b> The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib</p>
<p><u><a href="#">BR006</a></u></p> <p><input type="button" value="SCHEMA"/></p>	<p><b>REOPENED!</b> A Randomized Phase III Trial to Evaluate Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with <math>\geq 1</math> cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy.</p>
<p><u><a href="#">EA1181</a></u></p>	<p>Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response (CompassHER2-pCR)</p>
<p><u><a href="#">A011202</a></u></p> <p><input type="button" value="SCHEMA"/></p>	<p><b>(RT at SFMC, PCC, UPH, and Galesburg)</b> A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in breast Cancer Patients (cT1-3 N1) Who Have Positive Lymph Node Disease After Neoadjuvant Chemotherapy.</p>
<p><u><a href="#">B-59/GBG 96</a></u></p>	<p><b>(Bloomington, Peoria, Ottawa, Pekin, Peru, and Galesburg Only)</b>- A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo.</p>
<p><u><a href="#">A221505</a></u></p>	<p><b>(OSFMC, PCC RT, UPH, Galesburg)</b> – Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction</p>
<p><u><a href="#">EFC15935 / AMEERA-5</a></u></p> <p><input type="button" value="SCHEMA"/></p>	<p><b>NEW!</b> (Peoria only) A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease (<b>AMEERA-5</b>)</p>

**METASTATIC**

<p><u><a href="#">S2007</a></u></p> <p><input type="button" value="SCHEMA"/></p>	<p><b>NEW!</b> A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases</p>
<p><u><a href="#">BR002</a></u></p>	<p>(RT at SFMC (<b>suspended</b>) and UPH)- A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Diagnosed Oligometastatic Breast Cancer</p>

<a href="#"><u>BR004</u></a>	A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
<a href="#"><u>S1703</u></a>	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
<a href="#"><u>SGNTUC-016</u></a> 	Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
<a href="#"><u>SMX 20-001</u></a> 	<b>Galesburg)</b> An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII )
<b>CANCER CONTROL (Breast only)</b>	
<a href="#"><u>A191901</u></a> 	<b>NEW!</b> Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
<a href="#"><u>WF-1901</u></a>	<b>NEW!</b> Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
<a href="#"><u>ACCRU SC-1601</u></a> 	<b>(Peoria, Bloomington, Galesburg, Peru, Pekin and Ottawa only)</b> -A Phase III, Randomized, Controlled, Dose-Evaluation Study Evaluating the Safety of Two Doses of Apixaban For Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
<a href="#"><u>WF-97116</u></a>	<b>(Peoria, Galesburg, Bloomington, Ottawa, Peru and Pekin)</b> Phase III Placebo Controlled Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment.
<a href="#"><u>URCC 16070</u></a>	Treatment of Refractory Nausea- for breast cancer patients.
<a href="#"><u>A221602</u></a>	Olanzapine with our without Fosaprepitant for the Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo- Controlled Trial.
<a href="#"><u>URCC-18007</u></a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue in stage I-III Breast cancer pts.- <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#"><u>WF-30917CD</u></a>	A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
<a href="#"><u>URCC 16092</u></a>	<b>(Peoria only)</b> - Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer

## CANCER CONTROL

### MULTI-DISEASE SITES

<a href="#">A221602</a>	Olanzapine with or without Fosaprepitant for the Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo- Controlled Trial.
<a href="#">ACCRU SC-1601</a> <a href="#">SCHEMA</a>	<b>(Peoria, Bloomington, Galesburg, Peru, Pekin and Ottawa only)</b> -A Phase III, Randomized, Controlled, Dose-Evaluation Study Evaluating the Safety of Two Doses of Apixaban For Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
<a href="#">URCC 16092</a>	<b>(Peoria only)</b> - Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Cancer Patients Receiving Chemotherapy
<a href="#">WF-1901</a>	<b>NEW!</b> Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

### BREAST

<a href="#">A191901</a> <a href="#">SCHEMA</a>	<b>Coming Soon!</b> Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
<a href="#">URCC 16070</a>	Treatment of Refractory Nausea- for breast cancer patients.
<a href="#">URCC-18007</a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue in stage I-III Breast cancer pts.- <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#">WF-97116</a>	<b>(Peoria, Galesburg, Bloomington, Ottawa, Peru and Pekin)</b> Phase III Placebo Controlled Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment.

### LUNG

	Nothing currently available for Lung only - <i>See Multi-Disease Cancer Control trials ABOVE .</i>
--	--

### COLORECTAL

<a href="#">A221805</a> <a href="#">SCHEMA</a>	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
<a href="#">S1820</a>	A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
<a href="#">WF-1806</a>	(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer

### BRAIN

<a href="#">WF-1801</a>	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
-------------------------	--

### REGISTRY

Navigator - Jennifer B x3617

<a href="#">Connect MDS/AML</a>	<b>REOPENED!</b> The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry This also included ICUS. <i>(enrolling low risk MDS pts only)</i>
---------------------------------	--





ILLINOIS  
CANCERCARE, P.C.C.C.  
*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

FEBRUARY 2021



*CARCINOID*

Navigator - Ashton x3611  
Carrie x3621

*No trials at this time*



# MASTER TRIAL LIST

FEBRUARY 2021



CLL

Navigator - Heather x3661

**1st Line**

<p><u><a href="#">S1925</a></u></p>	<p><b>NEW!</b> Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): <b>EVOLVE</b> CLL/SLL Study</p>
<p><u><a href="#">U2-VEN-207</a></u></p> <p><small>SCHEMA</small></p>	<p><b>(Bloomington, Galesburg, Pekin, Peoria)</b> Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax (U2-V) in Subjects With Chronic Lymphocytic Leukemia (CLL) - <b>ULTRA-V</b> <i>(tx naïve arm temporarily closed - relapsed open)</i></p> <p><i>*NOTE: Medicare will not authorize Venetoclax</i></p>
<p><u><a href="#">A041702</a></u></p>	<p>A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (&gt;= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)</p>
<p><u><a href="#">EA9161</a></u></p>	<p>A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)</p>

**2nd Line, 3rd Line, etc.**

<p><u><a href="#">U2-VEN-207</a></u></p>	<p><b>(Bloomington, Galesburg, Pekin, Peoria)</b> Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax (U2-V) in Subjects With Chronic Lymphocytic Leukemia (CLL) - <b>ULTRA-V</b> <i>(tx naïve arm temporarily closed - relapsed open)</i></p>
--	---



ILLINOIS  
CANCERCARE, P.C.  
*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

FEBRUARY 2021



MENU

*CML*

Navigator - Heather x3661

*No trials at this time*

# MASTER TRIAL LIST

MENU

FEBRUARY 2021

## COLON / RECTAL

Navigator - Carrie x3621

### Adjuvant

<a href="#"><u>A021502</u></a>	Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
--------------------------------	--

<a href="#"><u>NRG GI005</u></a>	<b>Temporarily Closed</b> Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
----------------------------------	--

### Metastatic

<a href="#"><u>A021703</u></a>	Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
--------------------------------	--

<a href="#"><u>MK 7339-003</u></a> <a href="#">SCHEMA</a>	<b>(Peoria, Bloomington, Galesburg, Peru)</b> A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)
--	--

<a href="#"><u>GI004</u></a>	<b>REOPENED!</b> A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer
------------------------------	--

### CANCER CONTROL (Colorectal only)

<a href="#"><u>A221602</u></a>	Olanzapine with or without Fosaprepitant for the Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo- Controlled Trial.
--------------------------------	--

<p><u><a href="#">A221805</a></u></p>	<p><b>REOPENED!</b> Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study</p>
<p><u><a href="#">ACCRU SC-1601</a></u></p> <p><small>SCHEMA</small></p>	<p><b>(Peoria, Bloomington, Galesburg, Peru, Pekin and Ottawa only)</b>-A Phase III, Randomized, Controlled, Dose-Evaluation Study Evaluating the Safety of Two Doses of Apixaban For Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy</p>
<p><u><a href="#">S1820</a></u></p> <p><small>SCHEMA</small></p>	<p>A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)</p>
<p><u><a href="#">URCC 16092</a></u></p>	<p><b>(Peoria only)</b> - Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer</p>
<p><u><a href="#">WF-1901</a></u></p>	<p><b>NEW!</b> Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)</p>
<p><u><a href="#">WF-1806</a></u></p>	<p>(M&amp;M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer</p>

# MASTER TRIAL LIST

FEBRUARY 2021



<i>ESOPHAGEAL- GASTRIC</i>		Navigator - Carrie x3621
<a href="#">EA2183</a>	<a href="#">SCHEMA</a>	<b>(UPH only)</b> A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

# MASTER TRIAL LIST

FEBRUARY 2021

MENU

## HEAD & NECK

Navigator - Ashton x3611

<a href="#"><u>EA3161</u></a>	A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
<a href="#"><u>HN004</u></a>	<b>(RT at OSF and UPH)</b> -Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
<a href="#"><u>HN005</u></a>	<b>(UPH &amp; OSF)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer



## LYMPHOMA

### HL

S1826

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

SGN35-027

**NEW! (Bloomington, Galesburg, Ottawa, Pekin, Peoria, Peru)** Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

SCHEMA

### NHL

EA4181

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 Years Old With Untreated Mantle Cell Lymphoma

C2321001

**(Peoria only)** A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL) **(FL cohort open)**

SCHEMA

TG-1501-101

**(Peoria only)**-A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

### DLBCL



# MASTER TRIAL LIST

FEBRUARY 2021



## MDS

Navigator - Heather x3661

<p><a href="#"><u>Connect MDS/AML</u></a></p>	<p><b>REOPENED!</b> The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry This also included ICUS. <i>(enrolling low risk MDS pts only)</i></p>
<p><a href="#"><u>NHLBI-MDS</u></a></p>	<p><b>(Peoria, Bloomington and Galesburg only)</b> -The National Myelodysplastic Syndromes (MDS) Study</p>
<p><a href="#"><u>M15-954</u></a></p> <p><a href="#">SCHEMA</a></p>	<p><b>(Peoria, Bloomington, Galesburg, Pekin)</b> A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)</p>



# MASTER TRIAL LIST

FEBRUARY 2021



## MELANOMA

Navigator - Carrie x3621

<p><b><u>MK 7902-003</u></b></p> <p><a href="#">SCHEMA</a></p>	<p><b>(Bloomington, Galesburg, Pekin, Peoria)</b> A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma (<b>LEAP-003</b>)</p>
<p><b><u>S2000</u></b></p> <p><a href="#">SCHEMA</a></p>	<p>A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases</p>



# MASTER TRIAL LIST

FEBRUARY 2021



**MERKEL**

**Navigator - Carrie x3621**

<p><b><u>EA6174</u></b></p>	<p><b>(If tx with RT then OSF(pending) UPH, and Galesburg)</b> A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma</p>
-----------------------------	--



# MASTER TRIAL LIST

MENU

FEBRUARY 2021

## MOLECULAR STUDIES

\*Contact Disease Specific Navigator

<a href="#"><u>64091742PCR0002</u></a>	<b>Opening Jan 2021</b> Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer
<a href="#"><u>A151804</u></a>	Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
<a href="#"><u>ACCRU 2018-01</u></a>	<b>Temp. suspended (Peoria and Ottawa only)</b> - Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors(Bladder, Colorectal, Esophageal, Kidney/Renal pelvis, Ovarian, Pancreas, Stomach and Uterine.
<b>PCR PIC1009(Parker Institute)</b>	An Exploratory Biomarker Study of Checkpoint Inhibitors (PD-1, PD-L1 and CTLA-4) used as Monotherapy or in Combination in Patients with Cancer
<a href="#"><u>S1823</u></a>	A Study of miRNA 371 in Patients With Germ Cell Tumor

SCHEMA

# MASTER TRIAL LIST

FEBRUARY 2021



## *MULTIPLE MYELOMA*

Navigator - Heather x3661

**S1803**

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

**NSCLC**

Navigator - Ashton x3611

**ADJUVANT / NEOADJUVANT**

<p><a href="#">S1933</a> SCHEMA</p>	<p><b>(UPH only)</b> A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status</p>
<p><a href="#">A081801</a> SCHEMA</p>	<p>Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ALCHEMIST substudy- <i>Must be enrolled on ALCHEMIST and this substudy prior to start of tx.</i>)</p>
<p><a href="#">A151216</a></p>	<p>Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial <b>(ALCHEMIST)</b>.</p>
<p><a href="#">EA5181</a> SCHEMA</p>	<p><b>(UPH and Galesburg)</b> Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC <b>(credentialing pending at OSF)</b></p>
<p><a href="#">GO40241</a> SCHEMA</p>	<p><b>(Peoria, Bloomington, Galesburg, Pekin, Peru)</b> A Phase III, Double-Blinded, Multicenter, randomized Study Evaluating The Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer</p>
<p><a href="#">GO41854</a> SCHEMA</p>	<p><b>(Bloomington, Galesburg, Pekin, Peoria)</b> A Phase III, Open Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation <b>(SKYSCRAPER-03)</b></p>
<p><a href="#">S1914</a></p>	<p><b>(OSF Glen Oak, UPHM, Galesburg)</b> Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC</p>

**METASTATIC - 1st Line**

<p><a href="#">ADXS-503-101</a> SCHEMA</p>	<p><b>(Peoria only)</b> - Phase 1-2, Open Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous NSCLC <b>(Part A closed)</b></p>
<p><a href="#">LU002</a></p>	<p><b>(RT at OSF, UPH, Galesburg)</b>- Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial</p>
<p><a href="#">MK 7684A-003</a></p>	<p><b>Activation Planned March 2021</b> - (Bloomington, Galesburg, Ottawa, Pekin, Peoria, Peru) A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer</p>
<p><a href="#">TH-138</a> SCHEMA</p>	<p><b>(Peoria, Bloomington, Galesburg, Pekin)</b> Phase II Randomized Trial of Carboplatin + Pemetrexed+ Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked <b>(non smokers)</b></p>

**METASTATIC - 2nd/3rd Line**

<p><a href="#">ADXS-503-101</a> SCHEMA</p>	<p><b>(Peoria only)</b> - Phase 1-2, Open Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous NSCLC <b>(Part A closed)</b></p>
--	---

<a href="#"><u>CA209-79X</u></a>	<b>Activation Planned April/May 2021-</b> (Bloomington, Pekin, Galesburg, Peoria) A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy and Anti-PD-1 (L1) Immunotherapy ( <b>CheckMate 79X</b> )
<a href="#"><u>EA5191</u></a>	A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
<a href="#"><u>LUNAR Trial/EF-24</u></a> 	<b>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru)</b> Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure
<a href="#"><u>LUNGMAP</u></a>	A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC.
<a href="#"><u>TH-138</u></a> 	<b>(Peoria, Bloomington, Galesburg, Pekin)</b> Phase II Randomized Trial of Carboplatin + Pemetrexed+ Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked ( <b>EGFR mutants</b> )
<b>CANCER CONTROL (NSCLC Only)</b>	
<a href="#"><u>A221602</u></a>	Olanzapine with our without Fosaprepitant for the Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo- Controlled Trial.
<a href="#"><u>ACCRU SC-1601</u></a> 	<b>(Peoria, Bloomington, Galesburg, Peru, Pekin and Ottawa only)</b> -A Phase III, Randomized, Controlled, Dose-Evaluation Study Evaluating the Safety of Two Doses of Apixaban For Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
<a href="#"><u>URCC 16092</u></a>	<b>(Peoria only)</b> - Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
<a href="#"><u>WF-1901</u></a>	<b>NEW!</b> Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
<a href="#"><u>WF-30917CD</u></a>	A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors



# MASTER TRIAL LIST

FEBRUARY 2021



## PANCREATIC

Navigator - Carrie x3621

<a href="#"><u>*A021602</u></a>	Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo In Patients With Advanced Neuroendocrine Tumors After progression on Everlimus(CABINET)
<a href="#"><u>A021806</u></a> <a href="#">SCHEMA</a>	A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
<a href="#"><u>EA2186</u></a> <a href="#">SCHEMA</a>	A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
<a href="#"><u>D-US-60010-001</u></a> <a href="#">SCHEMA</a>	An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas ( <b>NAPOLI3</b> )

# MASTER TRIAL LIST

FEBRUARY 2021

MENU

## PROSTATE

Navigator - Carrie x3621

### ADJUVANT

<p><a href="#"><u>C2321001</u></a></p> <p><a href="#">SCHEMA</a></p>	<p><i>Prostate cohort temporarily closed (Peoria only)</i> A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL) (<i>FL cohort open</i>)</p>
<p><a href="#"><u>EA8183</u></a></p>	<p><i>RT Credentialing Pending</i> A Phase III Double Blinded Study of Early Intervention After RADICAL ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (<b>ERADICATE</b>)</p>
<p><a href="#"><u>GU002</u></a></p>	<p><b>(RT at SFMC, UPH, and ILCC)</b>–Phase II-III Trial of Adjuvant radiotherapy and Androgen Deprivation Following radical Prostatectomy with or without Adjuvant Docetaxel</p>
<p><a href="#"><u>GU005</u></a></p>	<p><b>(OSF &amp; UPH)</b>-Phase II IGRT and SBRT vs. IGRT and hypofractionate IMRT for Localized Intermediate Risk Prostate Cancer.</p>
<h3>METASTATIC</h3>	
<p><a href="#"><u>64091742PCR0002 / Prevalence</u></a></p>	<p><b>NEW!</b> Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer</p>
<p><a href="#"><u>EA8153</u></a></p>	<p>Cabazitaxel with Abiraterone versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial</p>
<p><a href="#"><u>S1802</u></a></p>	<p><b>(OSF &amp; UPH)</b> Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer</p>

# MASTER TRIAL LIST

FEBRUARY 2021



## RENAL CELL

Navigator - Carrie x3621

<p><a href="#"><u>A031704</u></a></p>	<p>PD-Inhibitor (nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)</p>
<p><a href="#"><u>EA8143</u></a></p>	<p>A Phase 3 Randomized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy(PROSPER RCC)</p>
<p><a href="#"><u>MK 6482-011</u></a></p> <p><a href="#">SCHEMA</a></p>	<p>(Peoria only) An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy</p>
<p><a href="#"><u>S1931</u></a></p> <p><a href="#">SCHEMA</a></p>	<p>Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)</p>

## RADIATION TRIALS

Navigator - Jessica x3615

<p><b><u>BN007</u></b></p> <p>SCHEMA</p>	<p><b>(UPH, OSF, Galesburg)</b> A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma</p>
<p><b><u>S1933</u></b></p> <p>SCHEMA</p>	<p><b>(UPH only)</b> A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status</p>
<p><b><u>EA5181</u></b></p> <p>SCHEMA</p>	<p><b>(UPH and Galesburg)</b> Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC <b>(credentialing pending at OSF)</b></p>
<p><b><u>EA2183</u></b></p> <p>SCHEMA</p>	<p><b>(UPH only)</b> A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)</p>
<p><b><u>MA.39</u></b></p>	<p><b>(OSFMC, and UPH)-</b> Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer</p>
<p><b><u>CCTG CE.7</u></b></p>	<p><b>(UPH &amp; OSF-glen oak)-</b> A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases</p>
<p><b><u>NRG CC003</u></b></p> <p>SCHEMA</p>	<p><b>(OSF only)</b> Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer</p>
<p><b><u>GU005</u></b></p>	<p><b>(OSF and UPH)</b> -Phase II IGRT and SBRT vs. IGRT and hypofractionate IMRT for Localized Intermediate Risk Prostate Cancer.</p>
<p><b><u>WF-1802</u></b></p>	<p>Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)</p>

<a href="#"><u>A071801</u></a>	<b>(UPH &amp; OSF-glen oak)</b> Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
<a href="#"><u>S1827</u></a>	<b>(OSF and UPH)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer
<a href="#"><u>NRG LU007</u></a>	<b>(OSF &amp; UPH)</b> – Randomized Phase II/III Trial of Consolidation RT + Immunotherapy for SCLC
<a href="#"><u>LU007 / RAPTOR</u></a>	<b>(OSF/UPH)</b> – Randomized Phase II/III Trial of Consolidation RT + Immunotherapy for ES-SCLC
<a href="#"><u>HN005</u></a>	<b>(UPH &amp; OSF)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
<b><i>CANCER CONTROL (RT specific)</i></b>	
<a href="#"><u>WF-1801</u></a>	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

## SMALL CELL LUNG CANCER

Navigator - Ashton x3611

<p><a href="#"><u>S1929</u></a></p> <p>SCHEMA</p>	<p>Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) <i>Tissue screening allowed during induction chemotherapy</i></p>
<p><a href="#"><u>G041767</u></a></p> <p>SCHEMA</p>	<p><b>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru)</b> A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer <b>(SKYSCRAPER-02)</b></p>
<p><a href="#"><u>Ipsen 398-01-03-04</u></a></p> <p>SCHEMA</p>	<p><b><i>Closing soon!</i></b> <b>(Peoria, Bloomington, Galesburg, Pekin)</b> A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On or After Platinum-Based First-Line Therapy. <b>(RESILIENT)</b></p>
<p><a href="#"><u>LU005</u></a></p>	<p><b>(OSF, UPH and Galesburg)</b> Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab</p>
<p><a href="#"><u>NRG CC003</u></a></p> <p>SCHEMA</p>	<p><b>(OSF only)</b> Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer</p>
<p><a href="#"><u>S1827</u></a></p>	<p><b>(OSF and UPH)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p>
<p><a href="#"><u>LU007 / RAPTOR</u></a></p>	<p><b>(OSF/UPH)</b> – Randomized Phase II/III Trial of Consolidation RT + Immunotherapy for ES-SCLC</p>



ILLINOIS  
CANCERCARE, P.C.  
*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

FEBRUARY 2021



MENU

**VULVA**

Navigator - Angie x3613

Figure 1-1: Study Design Schematic






Figure 1 Study Schema




ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor; NSCLC = non-small cell lung cancer; PORT = post-operative radiation therapy; PS = performance status.

**C2321001 SCHEMA**  
Contact Disease Specific Navigator

**MENU**




\*50-70% down modulation of H3K27me3



- \* Paclitaxel 80 mg/m<sup>2</sup> IV weekly x 12 doses (WP) + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles.
- \*\* Doxorubicin (A) 60 mg/m<sup>2</sup> IV + cyclophosphamide (C) 600 mg/m<sup>2</sup> IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m<sup>2</sup> IV + cyclophosphamide (C) 600 mg/m<sup>2</sup> IV Day 1 every 2 or 3 weeks for 4 cycles. Choice of anthracycline and schedule per investigator discretion.
- † Atezolizumab 1200 mg or placebo IV Day 1 every 3 weeks for 4 doses.
- †† Atezolizumab 1200 mg or placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.
- \*\*\* Atezolizumab 1200 mg or placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose.


**SGNTUC-016 SCHEMA**  
 Navigator - Angie x3613

**MENU**



**ADXS-503-101 SCHEMA**  
**Navigator - Ashton x3611**

**MENU**




**Figure 1. Study Design**

- Escalation to DL2 in Part A will occur in parallel with accrual at DL1 in Part B
- Escalation to DL2 in Part B will occur in parallel with accrual in Part C
- If treatment is not safe/tolerable at DL1 in Part A or Part B, a lower dose level (DL-1; 0.5x10<sup>8</sup> CFU of ADXS-503) will be evaluated before proceeding with Part B and Part C, respectively.
- Upon completion of dose escalation in Part A, ADXS-503 monotherapy may be evaluated in an expansion cohort.

Abbreviations: DL: dose level.

**EF-24-V2.1 (LUNAR) SCHEMA**  
Navigator - Ashton x3611

**MENU**



## Study Design






Figure 1 Study Schema



1L=first-line; CE=carboplatin and etoposide; ECOG PS=Eastern Cooperative Oncology Group performance status; ES-SCLC=extensive-stage small cell lung cancer; LDH=lactase dehydrogenase; RECIST=Response Evaluation Criteria in Solid Tumors.

<sup>a</sup> For the first 24 randomized patients (approximately 12 per arm), safety and tolerability data will be assessed by an independent Data Monitoring Committee.


Figure 5: Study Schema



Note: ONIVYDE is also known as irinotecan liposome injection, liposomal irinotecan or nal-IRI.


Each part will consist of three stages: screening stage, treatment/active follow-up stage and long-term follow-up stage. Once consented, patients will enter a screening stage. Upon first dose of study treatment in Part 1 or randomization (Part 2), patients will enter the treatment/active follow-up stage. Once a decision is made to permanently discontinue the patient from study treatment, a 30-day follow-up visit will occur and the patient will enter the long-term follow-up stage. The stages for this trial are outlined in the schematic below.

Figure 6: Description of Treatment Stages



US-VEN-207 (ULTRA-V) Schema  
Navigator - Heather x3661


MENU



US-VEN-207

MK 7902-003 (LEAP-003) Schema  
Navigator - Carrie x3621

MENU



**MK 6482-011 Schema**  
Navigator - Carrie x3621

**MENU**






Figure 2. Schema of TPX-0005-01 Study







- a Response assessments will include PET and diagnostic-quality CT scan on Day 25-28 of Cycle 2, and at EOT.
- b Part C follow-up period includes 2 additional years (5 years total).

GO41854 Schema  
Navigator - Ashton x3611


MENU



**Schema for patients who pre-register prior to SLN surgery:**




**Schema for patients who pre-register AFTER surgery\* (where SLN surgery was performed but ALND was NOT performed):**




\* Patients who are pre-registered after SLN surgery are NOT eligible to enroll onto the Arm Lymphedema Companion Study (A011201-S11)

Schema




All patients will receive oxaliplatin on both phases of the trial. Further, for all patients the 17<sup>th</sup> week of study drug will be a tapering period.


\* Additional patients will be recruited to the Phase III trial. The most promising dose of duloxetine will be determined after initial Phase II, and this dose will be used for Phase III for patients randomized to the duloxetine arm.




Schema



Schema: 1 cycle = 21 days



SCHEMA



\* Patients and providers will not have knowledge of the results of the miRNA 371 analysis.


**EA2186 SCHEMA**  
**Navigator - Carrie x3621**


**MENU**

**Schema**

Stratification:

- ECOG: 0-1 vs 2
- Age 70-74 vs  $\geq 75$





**SCHEMA**

**REGISTRATION STEP 1**



60 Gy hypofractionated radiotherapy in 15 fractions over 3 weeks



2-5 weeks after completion of radiotherapy:  
disease assessment

Progression



Off protocol treatment

No Progression




**REGISTRATION STEP 2**



Atezolizumab consolidation  
for up to 12 months  
(maximum of 17 cycles)

Schema



Merck 7339-003 / LYNK-003 SCHEMA  
Navigator -Carrie x3621

MENU

**Key Inclusion Criteria**

- Unresectable or metastatic CRC
- Has not progressed after completing at least 6 prior induction cycles of FOLFOX + bevacizumab and can no longer tolerate oxalliplatin
- ECOG 0-1

Stratification Factors:


- SD vs. PR/CR to prior FOLFOX induction
- BRAF<sub>mut</sub> and/or Ras<sub>mut</sub> vs. BRAF<sub>wt</sub> + Ras<sub>wt</sub>
- 6-8 cycles vs. >8 cycles of FOLFOX induction


R  
1:1:1

Olaparib Oral +  
Bevacizumab  
(until progression)


Olaparib Oral  
(until progression)

5-FU + Bevacizumab  
(until progression)






Schema




SMX 20-001  
Navigator -Angie x3613

**MENU**




**M15-954**  
**Navigator -Heather x3661**


**MENU**



FU = follow up; HSCT = hematopoietic stem cell transplant; IPSS-R = Revised International Prognostic Scoring System; LSFD = last subject first dose; MDS = myelodysplastic syndrome; QD = once daily




SCHEMA




EA2176  
Navigator -Carrie x3621


MENU




1. Randomization is 1:2 (A:B).

2. For this protocol, all patients, including those who discontinue protocol therapy early, will be followed for response until disease progression, even if non-protocol therapy is initiated, and for survival every 3 months for two years from the date of randomization. All patients must also be followed through completion of all protocol therapy.






Treatment/intervention is to continue as outlined above or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Patients will be followed for 6 years or until death, whichever comes first.



BICR=blinded independent central review; DMC=Data Monitoring Committee; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; QD=once daily; RCC=renal cell carcinoma; ROW=rest of world; TKI=tyrosine kinase inhibitor; US=United States; VEGF=vascular endothelial growth factor.

**Schema**


Cycle definition is based on ICI cycle length



\* ICI agents include pembrolizumab, nivolumab, atezolizumab, durvalumab and avelumab


Patients will be followed for 5 years or until death or withdrawal of consent, whichever occurs first.

Schema




**SCHEMA**

Newly Diagnosed, Early Stage, Asymptomatic, High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [CLL-International Prognostic Index (CLL-IPI)  $\geq 4$  and/or Complex Cytogenetics]




Schema



Accrual Goal: 810

1. Patients with a Decipher score previously performed by Decipher biosciences with a score of > 0.6 are eligible and may proceed from pre-registration directly to randomization after uploading Decipher score to Medidata Rave.
2. For patients who do not already have a completed Decipher test through standard of care testing the calculated CAPRA-S score must be  $\geq 3$  and the post registration Decipher Biosciences assessment must determine Decipher score to be > 0.6.
3. Patients receiving post-operative adjuvant radiation (XRT) can receive it anytime within 52 weeks of prostatectomy.

Figure 1 - Graphical study design



C = Cycle; D = day; IMP = Investigational medicinal product; PD = progressive disease; R = randomization.

**S1418 / BR006**  
**Navigator -Angie x3613**

**MENU**

Patients with TNBC\*,  $\geq 1$ cm residual invasive breast cancer, or any + LN (including ypN1mi) after neoadjuvant chemotherapy, followed by surgery

**Step 1 Registration**

Submit slides to central laboratory for PD-L1 evaluation.  
SWOG Statistics and Data Management Center will notify sites when PD-L1 testing is completed.

**Step 2 Registration (RANDOMIZATION)**

Randomization stratification factors will include:

- Nodal Stage: ypN0 vs. ypN+
- Residual tumor size:  $\leq 20$  mm vs.  $> 20$  mm
- PD-L1: positive vs. negative (blinded to sites)
- Prior post-operative (adjuvant) chemotherapy: yes vs. no

**Arm 1\*\***

Observation

**Arm 2\*\***

Pembrolizumab  
(MK-3475)  
IV  
every 3 weeks for 52  
weeks

\* Patients with low ER- and/or PR- positive cancers (less than or equal to 5% positivity) and/or HER2 borderline cancers by ASCO CAP guidelines are also eligible.

\*\* Patients must complete adjuvant chemotherapy, if given, prior to Step 1 Registration. Radiation therapy may be given concurrently with protocol treatment on Arm 1 or Arm 2 (see [Section 7.0](#)).